JP2025078629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025078629A5 JP2025078629A5 JP2025012821A JP2025012821A JP2025078629A5 JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5 JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025012821 A JP2025012821 A JP 2025012821A JP 2025078629 A5 JP2025078629 A5 JP 2025078629A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- antibody
- domain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206959.9A EP3816185A1 (en) | 2019-11-04 | 2019-11-04 | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| EP19206959.9 | 2019-11-04 | ||
| JP2022524675A JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
| PCT/EP2020/080941 WO2021089609A1 (en) | 2019-11-04 | 2020-11-04 | Multispecific antibody |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Division JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025078629A JP2025078629A (ja) | 2025-05-20 |
| JP2025078629A5 true JP2025078629A5 (cg-RX-API-DMAC7.html) | 2025-10-27 |
| JP7899374B2 JP7899374B2 (ja) | 2026-08-03 |
Family
ID=68426333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Pending JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
| JP2025012821A Active JP7899374B2 (ja) | 2019-11-04 | 2025-01-29 | 多重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524675A Pending JP2023501146A (ja) | 2019-11-04 | 2020-11-04 | 多重特異性抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220411536A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3816185A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023501146A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20260110258A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114981306A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020379182A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3159904A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292727A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021089609A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11319371B2 (en) * | 2017-06-05 | 2022-05-03 | Numab Therapeutics AG | Anti-CD3 antibodies |
| WO2022136693A1 (en) | 2020-12-23 | 2022-06-30 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| WO2022242682A1 (en) * | 2021-05-21 | 2022-11-24 | Beigene, Ltd. | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| US20240352153A1 (en) * | 2021-07-23 | 2024-10-24 | Akeso Biopharma, Inc | Pharmaceutical composition and use |
| CN117730103A (zh) * | 2021-08-02 | 2024-03-19 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
| WO2023088295A1 (zh) * | 2021-11-17 | 2023-05-25 | 江苏先声药业有限公司 | 一种多特异性抗体及其药物用途 |
| MX2024008500A (es) * | 2022-01-09 | 2024-08-26 | I Mab Biopharma Co Ltd | Construcciones multiespecíficas y usos de estas. |
| IL314169A (en) * | 2022-01-26 | 2024-09-01 | Zymeworks Bc Inc | Trispecific immunomodulatory T cell engager proteins |
| WO2023141856A1 (zh) * | 2022-01-27 | 2023-08-03 | 岩唐生物科技(杭州)有限责任公司 | 靶向cd3的多特异性抗体及其应用 |
| EP4524248A4 (en) * | 2022-05-12 | 2026-07-01 | Astellas Pharma Inc | MULTISPECIFIC ANTI-TAA AND ANTI-CD3 ANTIBODY |
| EP4540290A4 (en) * | 2022-06-14 | 2026-07-01 | Invenra Inc | Multi-species liaison agents targeting B7H3 and GD2, and their uses |
| WO2024036207A2 (en) * | 2022-08-11 | 2024-02-15 | University Of Florida Research Foundation, Incorporated | Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens |
| JP2025529310A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド | 多特異性構築物およびその使用 |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
| WO2024197709A1 (zh) * | 2023-03-30 | 2024-10-03 | 中国科学院深圳先进技术研究院 | 一种t细胞衔接器及其制备方法和应用 |
| WO2025016012A1 (en) * | 2023-07-14 | 2025-01-23 | Genor Biopharma Co., Ltd. | Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF |
| EP4754149A1 (en) * | 2023-07-29 | 2026-06-10 | Shanghai Kaijin Biotechnology , Ltd | Modified type e multi-specific antibodies |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| US7608681B2 (en) | 1999-12-24 | 2009-10-27 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US20040071705A1 (en) | 2002-06-21 | 2004-04-15 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| US8921528B2 (en) | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| KR20060095385A (ko) | 2005-02-28 | 2006-08-31 | 엘지전자 주식회사 | 세탁기의 헹굼 행정 제어 방법 |
| EP2535350B1 (en) | 2007-09-26 | 2018-01-24 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US10407513B2 (en) | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| WO2011006915A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| WO2016011069A1 (en) * | 2014-07-15 | 2016-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists (antibodies) |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| KR20250091329A (ko) | 2015-06-15 | 2025-06-20 | 누맙 세러퓨틱스 아게 | 이종 이량체 다중 특이적 항체 포맷 |
| IL304871A (en) | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| BR112018071612A2 (pt) | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| KR102379464B1 (ko) * | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| AR110348A1 (es) * | 2016-12-07 | 2019-03-20 | Agenus Inc | Anticuerpos y métodos de su utilización |
| US12098203B2 (en) * | 2017-06-05 | 2024-09-24 | Numab Therapeutics AG | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA |
| WO2018224439A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| IL273578B2 (en) * | 2017-10-10 | 2026-03-01 | Numab Therapeutics AG | Antibodies directed against PD-1 and methods of use thereof |
| EP3470426A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| US12202911B2 (en) * | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| EP3470429A1 (en) * | 2017-10-10 | 2019-04-17 | Numab Innovation AG | Antibodies targeting pdl1 and methods of use thereof |
| WO2019166650A1 (en) * | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
| CN109942704B (zh) * | 2019-04-12 | 2023-01-20 | 深圳普瑞金生物药业股份有限公司 | Hsa单域抗体、核酸及试剂盒 |
| MX2022014768A (es) * | 2020-05-29 | 2023-01-11 | Numab Therapeutics AG | Anticuerpo multiespecifico. |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| AU2021405066A1 (en) * | 2020-12-23 | 2023-06-22 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| JP7858665B2 (ja) * | 2021-02-02 | 2026-05-14 | ヌマブ セラピューティックス アーゲー | Ror1およびcd3に対する特異性を有する多重特異性抗体 |
-
2019
- 2019-11-04 EP EP19206959.9A patent/EP3816185A1/en not_active Ceased
-
2020
- 2020-11-04 CN CN202080091252.3A patent/CN114981306A/zh active Pending
- 2020-11-04 CA CA3159904A patent/CA3159904A1/en active Pending
- 2020-11-04 EP EP20799711.5A patent/EP4055045A1/en active Pending
- 2020-11-04 KR KR1020267020312A patent/KR20260110258A/ko active Pending
- 2020-11-04 KR KR1020227018543A patent/KR20220092949A/ko not_active Ceased
- 2020-11-04 US US17/771,836 patent/US20220411536A1/en active Pending
- 2020-11-04 AU AU2020379182A patent/AU2020379182A1/en active Pending
- 2020-11-04 WO PCT/EP2020/080941 patent/WO2021089609A1/en not_active Ceased
- 2020-11-04 JP JP2022524675A patent/JP2023501146A/ja active Pending
-
2022
- 2022-05-03 IL IL292727A patent/IL292727A/en unknown
-
2025
- 2025-01-29 JP JP2025012821A patent/JP7899374B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hayden et al. | Antibody engineering | |
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2022548796A5 (cg-RX-API-DMAC7.html) | ||
| JP2022514693A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518142A5 (cg-RX-API-DMAC7.html) | ||
| IL312224B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| HRP20251135T1 (hr) | Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore | |
| US20220396635A1 (en) | Trivalent binding molecules | |
| CN108610420A (zh) | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 | |
| CN106883297A (zh) | 基于ch3结构域的异二聚体分子、其制备方法及用途 | |
| JP2024508672A5 (cg-RX-API-DMAC7.html) | ||
| CN114127111A (zh) | 与nkp30结合的抗体分子及其用途 | |
| JP2025508316A5 (cg-RX-API-DMAC7.html) | ||
| CN104829727B (zh) | 一种双特异性抗体cd19×cd3的构建及应用 | |
| JP2023525720A5 (cg-RX-API-DMAC7.html) | ||
| JP2024511423A5 (cg-RX-API-DMAC7.html) | ||
| JP2020522267A (ja) | 少なくともcd3及びhsaを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP2020535796A5 (cg-RX-API-DMAC7.html) | ||
| US20230002488A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| EP4139346A1 (en) | Heterodimeric proteins | |
| Loh et al. | Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies | |
| WO2022093694A1 (en) | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| CN112940136B (zh) | 一种嵌合抗原结合受体car、载体、car-t细胞、药物组合物及其应用 |